Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NANO-X IMAGING LTD (Nanox) SEC filings page for ticker NNOX provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ. Nanox files an annual report on Form 20-F and furnishes current reports on Form 6-K that cover topics such as capital raises, financial results, shareholder meetings, and significant business developments related to its medical imaging and AI platform.
Recent Form 6-K filings describe a registered direct offering of ordinary shares under an effective shelf registration statement on Form F-3, including the related placement agency agreement, purchase agreement, and legal opinions. Other 6-K reports furnish press releases announcing quarterly financial results, non-GAAP financial measures reconciled to GAAP, and notices and proxy materials for the company’s annual general meeting of shareholders. These documents allow investors to review how Nanox funds its operations and how it reports performance across its Nanox.ARC, radiology services, and AI solutions divisions.
Through this page, users can also track filings that reference Nanox’s imaging systems and AI solutions, including disclosures about commercialization activities, acquisitions such as VasoHealthcare IT, and integration of AI software with health IT infrastructure. The exhibits to these filings may include agreements, opinions, and other materials that provide additional context on Nanox’s operations and capital structure.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand items such as registered offerings, financial updates, or meeting notices. Real-time updates from EDGAR ensure that new 6-Ks, 20-Fs, and related registration statements appear promptly, while dedicated sections highlight ownership and insider-related filings when available. This combination of original SEC documents and AI-generated insights helps investors and researchers analyze NNOX regulatory information more efficiently.
Daniel Ran, listed as the Chief Financial Officer of Nano-X Imaging Ltd. (NNOX), reported a direct purchase of ordinary shares on 09/05/2025. The Form 4 shows he acquired 1,000 ordinary shares at a price of $3.65 per share and, following the transaction, beneficially owned 6,950 ordinary shares in total. The filing indicates this is an individual filing by one reporting person and includes no derivative transactions.
Daniel Ran filed an Initial Statement of Beneficial Ownership (Form 3) for Nano-X Imaging Ltd. (NNOX) dated 09/05/2025. The filing shows Mr. Ran is an officer (CFO) and a director and beneficially owns 5,950 ordinary shares directly. He also holds two option grants exercisable for ordinary shares: 40,000 options exercisable from 09/30/2022 and expiring 09/30/2031 with an exercise price of $23.86, and 55,000 options exercisable from 05/23/2024 and expiring 05/23/2033 with an exercise price of $11.52. The filing lists a Forest Hills, NY address for the reporting person and is signed by Daniel Ran on 09/05/2025.
NANO-X IMAGING LTD furnished an update for August 2025 noting that it issued a press release on August 12, 2025, which is attached as an exhibit. The release includes financial results that use non-GAAP measures, meaning certain items are adjusted out of the standard U.S. GAAP figures.
The non-GAAP metrics specifically exclude legal and related expenses tied to legal matters described in note 3 to the company’s condensed consolidated financial statements. The GAAP financial statement tables in the press release are also incorporated by reference into the company’s existing Form F-3 and Form S-8 registration statements.